CREG matching for first cadaveric kidney transplants (TNX) performed by SEOPF centers between October 1987 and September 1995

Clinical Transplantation

Volumn 10, Issue 6 II, 1996, Pages 586-593

  Thompson, John S ^a   Thacker, Leroy R ^b  

^a LEXINGTON VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

CREG class I; Histocompatibility; Kidney transplants; One and three year outcome

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN;

ARTICLE; CADAVER KIDNEY; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECIPIENT;

ALGORITHMS; CONTINENTAL POPULATION GROUPS; CROSS REACTIONS; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEALTH SERVICES ACCESSIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; SOUTHEASTERN UNITED STATES; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION, HOMOLOGOUS; WAITING LISTS;

EID: 0030462205     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chapter IV UNOS Activities Related to Minority Issues. In the National Organ Procurement and Transplantation Network 1994 Annual Report. pp VI-9, VI-10.
2. THOMPSON, JS. American Society of Histocompatibility and Immunogenetics crossmatch study. Transplantation 1995: 59: 1636.
3. THOMPSON JS. The case for years of functioning kidney transplant (YFT). In TERASAKI PI, CECKA M. eds. Clinical Transplants 1994. UCLA Tissue Typing Laboratory. Los Angeles, CA 1994, pp 436-441.
4. LEFFELL MS, STEINBERG AG, BIAS WB, MACHAN CH, ZACHARY AA. The distribution of HLA antigens and phenotypes among donors and patients in the UNOS registry. Transplantation 1994: 58: 1119.
5. SVEJGAARD A, KISSMEYER-NIELSEN F. Cross-reactive human HL-A isoantibodies. Nature (London) 1968: 219: 868.
6. LOBO PI. Development of anti-HLA antibodies following renal transplantation-their characteristics and natural history. Tissue Antigens 1982: 19: 356.
7. DUQUESNOY RJ, WHITE LT, FIERST JW. et al. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Transplantation 1983: 36 : 629.
8. KONOEDA Y, TERASAKI PI, WAKJSAKA A, PARK MS, MICKEY MR. Public determinants of HLA indicated by pregnancy antibodies. Transplantation 1986: 41 : 253.
9. RODEY GE, NEYLAN JF, WHEECHEL JD, REVELS KW, BRAY RA. Epitope specificity of HLA Class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Human Immunol 1994: 39: 272.
10. SANFILIPPO F, VAUGHN WK, SPEES EK, HEISE ER, LEFOR WM. The effect of HLA-A,B matching on cadaver renal allograft rejection comparing public and private specificities. Transplantation 1984: 38: 483.
11. RODEY GE, FULLER TC. Public epitopes and the antigenic structure of the HLA molecules. CRC Crit Rev Immunol 1987: 7: 229.
12. TIKEMOTO S, GJERTSON DW, TERASAKI PI. HLA matching: a comparison of conventional and molecular approaches. In TERASAKI PI, CECKA M. eds. Clinical Transplants 1992. UCLA Tissue Typing Laboratory, Los Angeles, CA., 1992, pp413-434.
13. TAKEMOTO S, TERASAKI PI, GJERTSON DW, CECKA JM. Equitable Allocation of HLA-compatible kidneys for local pools and minorities. N Engl J Med 1994: 331: 760.
14. MCDONALD JC, VAUGHN W, FILO RS. et al. Cadaver donor transplantation by centers of the South-Eastern Organ Procurement Foundation. Ann Surg 1984: 200: 535.
15. PETERS TG, VAUGHN WK, WILLIAMS JW, SPEES EK. Methyldopa therapy and outcome in cadaveric renal transplantation. South Med J 1985: 78: 1004.
16. SAS INSTITUTE INC. SAS/STAT User's Guide. Fourth Edition. Vol 2.Cary, NC:SAS Institute Inc., 1989. 846pp.
17. BRESLOW N. A generalized Kruskal-Wallace test for comparing k samples subject to unequal patterns of censorship. Biometrika 1970: 57: 579.
18. MANTEL N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966: 50: 163.